Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin Commits Up to US$10 Million in 4BIO Venture Fund, Its 1st VC Investment
June 18, 2020
- Takeda Out-Licenses 7 Psych Programs to Neurocrine
June 18, 2020
- Canada OKs Sunovion’s Apomorphine Sublingual Film for Parkinson’s
June 17, 2020
- 10 Foreign Makers in Japan Grow Above Market with 5.5% Sales Rise in 2019
June 17, 2020
- Distributors See 800 Item Shortages as Good Guesstimate as They Share Off-Year Survey Concerns with Chuikyo Wholesaler Rep
June 17, 2020
- Astellas Relaxes Commuting Rate Limit to 50% at HQ as COVID-19 Situation Improves
June 17, 2020
- Oncolys Inks US$300 Million-Plus Pact for OBP-601; Potential for Neurodegenerative Diseases Eyed
June 16, 2020
- Meiji/Solasia Plan Japan NDA for PTCL Med in First Half of 2021
June 16, 2020
- Taiho Files Aloxi for Pediatric Use
June 16, 2020
- Poteligeo Now Available in Germany: Kyowa Kirin
June 16, 2020
- Mitsubishi Tanabe Launches PIII Dersimelagon Study for Rare Protoporphyria, Targeting US Filing in FY2021
June 16, 2020
- Kaken’s Axillary Hyperhidrosis Treatment Hits Primary Goal in Japan PIII Study
June 16, 2020
- 26 Japan Drug Makers Generate 56.4% of Sales Overseas in FY2019, Shire Buy Gives Boost: Tally
June 15, 2020
- Otsuka’s ADHD Med Hits Primary Goal in US PIII Trials
June 15, 2020
- Takeda, Mitsubishi-UBS Asset JV to Collaborate in Shonan iPark Operations
June 15, 2020
- PeptiDream, US Merck Link Up to Develop COVID-19 Treatment
June 15, 2020
- Daiichi Sankyo to Kickstart COVID-19 Vaccine Development
June 15, 2020
- AbbVie Files Rinvoq for Psoriatic Arthritis in Japan
June 15, 2020
- Takeda to Divest 18 Non-Core Meds in Asia-Pacific to Celltrion for US$278 Million
June 12, 2020
- Ono/Seikagaku’s Novel Osteoarthritis Drug Delivers in Japan PIII for Knee Pain
June 12, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…